Compugen Ltd (CGEN) 7.83 $CGEN
RTM Consulting to Present 'Consulting Soft Skills: Mission Critical for B4B Suppliers' at Technology Services World
Marketwired - Wed Oct 15, 9:11AM CDT
Cincinnati-based RTM Consulting, the leading provider of Resource Management solutions for consulting, professional and support services organizations in the IT sector, today announced they will co-present with the Technology Services Industry Association (TSIA) and RTM Consulting clients Compugen, Medidata Solutions and Ontario Systems at Technology Services World 2014 Service Transformations conference, taking place October 20 - 22 at the ARIA Resort in Las Vegas. The Technology Services World conference has become renowned as the preeminent source of learning and peer networking for technology services professionals.
MDSO: 42.15 (+0.88), CGEN: 7.83 (+0.13)
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Tue Oct 14, 1:02PM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced today relates to the second preclinical milestone for one of the checkpoint protein candidates. The achievement of the initial milestone for this candidate was announced in July of this year.
CGEN: 7.83 (+0.13)
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
Business Wire - Mon Oct 06, 6:08AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
CGEN: 7.83 (+0.13)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ACE: 106.70 (+1.61), COF: 78.70 (+2.20), CBK: 6.39 (+0.01), CGEN: 7.83 (+0.13), BPFH: 12.00 (+0.20)
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy
Business Wire - Wed Oct 01, 6:01AM CDT
--CGEN-15049 therapeutic antibody development is underway
CGEN: 7.83 (+0.13)
Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction
Business Wire - Mon Sep 29, 6:04AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today that experimental results supporting CGEN-15001's induction of long-term autoimmune disease remission in disease animal models, potentially through a novel mechanism of action, are being presented at two sessions at the 3rd International Conference on Immune Tolerance, now being held in Amsterdam, the Netherlands, from September 28-30, 2014. The presentations are being given by Joseph R. Podojil, PhD, of Northwestern University Feinberg School of Medicine, and by Iris Hecht, PhD, Principal Scientist at Compugen.
CGEN: 7.83 (+0.13)
Compugen Signs Multi-Year Contract With FortisBC
Marketwire Canada - Tue Sep 23, 11:00AM CDT
Compugen Inc. is pleased to announce that it has signed a multi-year contract to supply FortisBC with IT Customer and Infrastructure Services starting January 2015. This contract will see Compugen's Managed Services division take responsibility for all of the IT Operations, ITSM Processes and Tools, including the support of 2,500 employees and contractors involved in the company's natural gas operations in over 65 locations across British Columbia.
CGEN: 7.83 (+0.13)
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.97 (+0.03), CGEN: 7.83 (+0.13), SPPI: 7.62 (+0.13), CBLI: 0.38 (unch)
Can The Uptrend Continue for Compugen (CGEN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:32AM CDT
Can The Uptrend Continue for Compugen (CGEN)?
CGEN: 7.83 (+0.13)
Compugen Honoured as a Winner of Microsoft's Excellence in Operations -- Gold Level Award
Marketwire Canada - Thu Sep 04, 11:00AM CDT
Today Compugen announced it has won the Gold Level Excellence in Operations Award for delivering market-leading operational excellence supporting Microsoft technology over the past year.
CGEN: 7.83 (+0.13)
Compugen (CGEN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:39AM CDT
Compugen is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
CGEN: 7.83 (+0.13)
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
A: 54.00 (+1.65), OSIR: 13.01 (+0.09), ILMN: 179.55 (+15.08), LMNX: 19.72 (+0.25), AFFX: 7.68 (+0.12), QGEN: 22.58 (+0.46), BCOR: 15.37 (+0.19), ACCL: 12.51 (+0.03), ABT: 42.39 (+0.93), INCY: 52.44 (+1.65), BMY: 51.95 (+1.39), WAT: 107.17 (+9.63), ISIS: 41.12 (-0.06), SIAL: 135.60 (+0.61), BASI: 2.39 (-0.01), MRK: 55.13 (+1.08), CGEN: 7.83 (+0.13), CRL: 62.23 (+1.80), CELGZ: 3.57 (-0.14), NVS: 88.61 (+0.71)
Compugen Has Returned 14.7% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Aug 28, 4:59PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 14.71% as of today's recent price of $8.84.
CGEN: 7.83 (+0.13)
Compugen elects Ari Krashin as CFO
M2 - Tue Aug 26, 7:23AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) disclosed on Monday the addition of Ari Krashin as its chief financial officer.
CGEN: 7.83 (+0.13)
Compugen names Ari Krashin as new CFO
M2 - Tue Aug 26, 4:39AM CDT
Compugen Ltd (Nasdaq:CGEN), a drug discovery company, announced on Monday the appointment of Ari Krashin as chief financial officer, effective 9 September 2014.
GILT: 4.84 (-0.02), CGEN: 7.83 (+0.13)
Compugen Appoints Mr. Ari Krashin as Chief Financial Officer
Business Wire - Mon Aug 25, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies in the fields of immunology and oncology, today announced the appointment of Mr. Ari Krashin as Chief Financial Officer, effective as of September 9, 2014. Mr. Krashin will report to Dr. Anat Cohen Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for all financial functions of the company, including investor relations, and in addition will oversee the legal function.
GILT: 4.84 (-0.02), CGEN: 7.83 (+0.13)
Shares of CGEN Down 16.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Aug 21, 11:09AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 16.64% as of today's recent price of $8.64.
CGEN: 7.83 (+0.13)
Compugen Reacquires Baize's Financial Interest in Pipeline Product Candidates
Business Wire - Thu Aug 21, 6:10AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a termination and equity conversion agreement with Baize Investments (Israel) Ltd. ("Baize"
, pursuant to which the Company has reacquired Baize's participation rights for certain Pipeline Program candidates. In addition, a warrant to purchase 500,000 Compugen ordinary shares at $7.50 per share previously issued to Baize has been cancelled.
CGEN: 7.83 (+0.13)
RTM Consulting to Present 'Consulting Soft Skills: Mission Critical for B4B Suppliers' at Technology Services World
Marketwired - Wed Oct 15, 9:11AM CDT
Cincinnati-based RTM Consulting, the leading provider of Resource Management solutions for consulting, professional and support services organizations in the IT sector, today announced they will co-present with the Technology Services Industry Association (TSIA) and RTM Consulting clients Compugen, Medidata Solutions and Ontario Systems at Technology Services World 2014 Service Transformations conference, taking place October 20 - 22 at the ARIA Resort in Las Vegas. The Technology Services World conference has become renowned as the preeminent source of learning and peer networking for technology services professionals.
MDSO: 42.15 (+0.88), CGEN: 7.83 (+0.13)
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Tue Oct 14, 1:02PM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced today relates to the second preclinical milestone for one of the checkpoint protein candidates. The achievement of the initial milestone for this candidate was announced in July of this year.
CGEN: 7.83 (+0.13)
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
Business Wire - Mon Oct 06, 6:08AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
CGEN: 7.83 (+0.13)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ACE: 106.70 (+1.61), COF: 78.70 (+2.20), CBK: 6.39 (+0.01), CGEN: 7.83 (+0.13), BPFH: 12.00 (+0.20)
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy
Business Wire - Wed Oct 01, 6:01AM CDT
--CGEN-15049 therapeutic antibody development is underway
CGEN: 7.83 (+0.13)
Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction
Business Wire - Mon Sep 29, 6:04AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today that experimental results supporting CGEN-15001's induction of long-term autoimmune disease remission in disease animal models, potentially through a novel mechanism of action, are being presented at two sessions at the 3rd International Conference on Immune Tolerance, now being held in Amsterdam, the Netherlands, from September 28-30, 2014. The presentations are being given by Joseph R. Podojil, PhD, of Northwestern University Feinberg School of Medicine, and by Iris Hecht, PhD, Principal Scientist at Compugen.
CGEN: 7.83 (+0.13)
Compugen Signs Multi-Year Contract With FortisBC
Marketwire Canada - Tue Sep 23, 11:00AM CDT
Compugen Inc. is pleased to announce that it has signed a multi-year contract to supply FortisBC with IT Customer and Infrastructure Services starting January 2015. This contract will see Compugen's Managed Services division take responsibility for all of the IT Operations, ITSM Processes and Tools, including the support of 2,500 employees and contractors involved in the company's natural gas operations in over 65 locations across British Columbia.
CGEN: 7.83 (+0.13)
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.97 (+0.03), CGEN: 7.83 (+0.13), SPPI: 7.62 (+0.13), CBLI: 0.38 (unch)
Can The Uptrend Continue for Compugen (CGEN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:32AM CDT
Can The Uptrend Continue for Compugen (CGEN)?
CGEN: 7.83 (+0.13)
Compugen Honoured as a Winner of Microsoft's Excellence in Operations -- Gold Level Award
Marketwire Canada - Thu Sep 04, 11:00AM CDT
Today Compugen announced it has won the Gold Level Excellence in Operations Award for delivering market-leading operational excellence supporting Microsoft technology over the past year.
CGEN: 7.83 (+0.13)
Compugen (CGEN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:39AM CDT
Compugen is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
CGEN: 7.83 (+0.13)
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery A: 54.00 (+1.65), OSIR: 13.01 (+0.09), ILMN: 179.55 (+15.08), LMNX: 19.72 (+0.25), AFFX: 7.68 (+0.12), QGEN: 22.58 (+0.46), BCOR: 15.37 (+0.19), ACCL: 12.51 (+0.03), ABT: 42.39 (+0.93), INCY: 52.44 (+1.65), BMY: 51.95 (+1.39), WAT: 107.17 (+9.63), ISIS: 41.12 (-0.06), SIAL: 135.60 (+0.61), BASI: 2.39 (-0.01), MRK: 55.13 (+1.08), CGEN: 7.83 (+0.13), CRL: 62.23 (+1.80), CELGZ: 3.57 (-0.14), NVS: 88.61 (+0.71)
Compugen Has Returned 14.7% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Aug 28, 4:59PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 14.71% as of today's recent price of $8.84.
CGEN: 7.83 (+0.13)
Compugen elects Ari Krashin as CFO
M2 - Tue Aug 26, 7:23AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) disclosed on Monday the addition of Ari Krashin as its chief financial officer.
CGEN: 7.83 (+0.13)
Compugen names Ari Krashin as new CFO
M2 - Tue Aug 26, 4:39AM CDT
Compugen Ltd (Nasdaq:CGEN), a drug discovery company, announced on Monday the appointment of Ari Krashin as chief financial officer, effective 9 September 2014.
GILT: 4.84 (-0.02), CGEN: 7.83 (+0.13)
Compugen Appoints Mr. Ari Krashin as Chief Financial Officer
Business Wire - Mon Aug 25, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies in the fields of immunology and oncology, today announced the appointment of Mr. Ari Krashin as Chief Financial Officer, effective as of September 9, 2014. Mr. Krashin will report to Dr. Anat Cohen Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for all financial functions of the company, including investor relations, and in addition will oversee the legal function.
GILT: 4.84 (-0.02), CGEN: 7.83 (+0.13)
Shares of CGEN Down 16.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Aug 21, 11:09AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 16.64% as of today's recent price of $8.64.
CGEN: 7.83 (+0.13)
Compugen Reacquires Baize's Financial Interest in Pipeline Product Candidates
Business Wire - Thu Aug 21, 6:10AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a termination and equity conversion agreement with Baize Investments (Israel) Ltd. ("Baize"
, pursuant to which the Company has reacquired Baize's participation rights for certain Pipeline Program candidates. In addition, a warrant to purchase 500,000 Compugen ordinary shares at $7.50 per share previously issued to Baize has been cancelled. CGEN: 7.83 (+0.13)
